This article provides a comprehensive overview of the risks associated with the administration of chemotherapy, monoclonal antibodies and targeted or biological therapies in the management of solid tumours. The main physiological actions of these agents will be discussed, with reference to the immediate infusion-related side effects and complications that may arise from an extravasation injury. The article will focus on the identification and early recognition of these risk factors to implement preventive measures and appropriate management strategies.